Many positive outcomes related to cardiorenal function due to the use of SGLT-2 inhibitors, including improvements in heart failure, blood pressure, cardioprotective effects in patients with ASCVD, nephroprotection, renal protection, reduction in the loss of eGFR, prevention of kidney failure, and reduction in the risk of cardiovascular events and mortality in both diabetic and non-diabetic patients, are reported. Here, SLC5A2 is linked to heart failure.